These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31714285)

  • 21. Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.
    Yaribeygi H; Atkin SL; Montecucco F; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():8163153. PubMed ID: 34471642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes.
    Farngren J; Ahrén B
    Metabolism; 2019 Oct; 99():25-31. PubMed ID: 31279738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
    Michos ED; Tuttle KR
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
    [No Abstract]   [Full Text] [Related]  

  • 25. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incretin-based therapies, glucometabolic health and endovascular inflammation.
    Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
    Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ; Thomas MC
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
    [No Abstract]   [Full Text] [Related]  

  • 29. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
    Mosterd CM; Bjornstad P; van Raalte DH
    J Nephrol; 2020 Oct; 33(5):965-975. PubMed ID: 32356231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.
    Neumiller JJ
    Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):276-88. PubMed ID: 22827291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2020 Jun; 19(1):74. PubMed ID: 32522260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The journey to understanding incretin systems: Theory, practice and more theory.
    Yabe D; Kuwata H; Seino Y
    J Diabetes Investig; 2019 Sep; 10(5):1171-1173. PubMed ID: 31361402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
    Nangaku M; Wanner C
    Kidney Int; 2021 Feb; 99(2):318-322. PubMed ID: 33509354
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.
    Egger A; Kraenzlin ME; Meier C
    Curr Osteoporos Rep; 2016 Dec; 14(6):345-350. PubMed ID: 27709509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.